Skip to main content
. Author manuscript; available in PMC: 2020 Dec 29.
Published in final edited form as: Target Oncol. 2019 Oct;14(5):613–618. doi: 10.1007/s11523-019-00661-5

Table 3.

Toxicities attributed to GGTI-2418 occurring in at least two subjects or Grade ≥ 3

Grade 1 Grade 2 Grade 3 Grade 4
Nausea 8 (57%) 1 (7%)
Diarrhea 2 (14%) 2 (14%)
Fatigue 4 (28%)
Pruritis 1 (7%) 2 (14%)
Neutropenia 1 (7%) 1 (7%)
Decreased appetite 2 (14%)
Bilirubina 1 (7%) 1a (7%)
Elevated alkaline phosphatase 1a (7%)
Elevated aspartate aminotransferase (AST) 1 (7%) 1a (7%)
Elevated alanine aminotransferase (ALT) 2a (14%)
a

Concurrent with malignant biliary obstruction due to disease progression